Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy

Current genome-wide studies have indicated that a great number of long non-coding RNAs (lncRNAs) are transcribed from the human genome and appeared as crucial regulators in a variety of cellular processes. Many studies have displayed a significant function of lncRNAs in the regulation of autophagy. Autophagy is a macromolecular procedure in cells in which intracellular substrates and damaged organelles are broken down and recycled to relieve cell stress resulting from nutritional deprivation, irradiation, hypoxia, and cytotoxic agents. Autophagy can be a double-edged sword and play either a protective or a damaging role in cells depending on its activation status and other cellular situations, and its dysregulation is related to tumorigenesis in various solid tumors. Autophagy induced by various therapies has been shown as a unique mechanism of resistance to anti-cancer drugs. Growing evidence is showing the important role of lncRNAs in modulating drug resistance via the regulation of autophagy in a variety of cancers. The role of lncRNAs in drug resistance of cancers is controversial; they may promote or suppress drug resistance via either activation or inhibition of autophagy. Mechanisms by which lncRNAs regulate autophagy to affect drug resistance are different, mainly mediated by the negative regulation of micro RNAs. In this review, we summarize recent studies that investigated the role of lncRNAs/autophagy axis in drug resistance of different types of solid tumors.

Translational research of new developments in targeted therapy of colorectal cancer

A severe global health concern is the rising incidence and mortality rate of colorectal cancer (CRC). Chemotherapy, which is typically used to treat CRC, is known to have limited specificity and can have noticeable side effects. A paradigm shift in cancer treatment has been brought about by the development of targeted therapies, which has led to the appearance of pharmacological agents with improved efficacy and decreased toxicity. Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), and BRAF are among the molecular targets covered in this review that are used in targeted therapy for CRC. The current discussion also covers advancements in targeted therapeutic approaches, such as antibody-drug conjugates, immune checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. A review of the clinical trials and application of these particular therapies in treating CRC is also done. Despite the improvements in targeted therapy for CRC, problems such as drug resistance and patient selection remain to be solved. Despite this, targeted therapies have offered fresh possibilities for identifying and treating CRC, paving the way for the development of personalized medicine and extending the life expectancy and general well-being of CRC patients.

Association between maternal exposure to arsenic by drinking water during pregnancy and risk of preterm birth: a systematic review and meta-analysis

The relation of exposure to arsenic in drinking water during pregnancy to the risk of preterm birth (PTB) was contradictory. This meta-analysis aimed to examine the association between drinking water arsenic and PTB. A systematic search in PubMed and Scopus was performed to achieve all relevant studies. Odds ratios (OR) and 95% confidence intervals (CI) were used to pool data using the random-effect models. Overall, 11 studies with a total sample size of 3,404,189 participants were included in the meta-analysis. Arsenic exposure through drinking water during pregnancy was related to an increased risk of PTB (OR = 1.06; 95%CI = 1.01-1.10 for highest versus lowest category of arsenic), with significant heterogeneity across the studies (I2 = 84.8%, P = 0.001). This finding was supported by cohort studies (OR = 1.05; 95%CI = 1.01-1.10). This meta-analysis proposes that higher arsenic exposure in drinking water may be a risk factor for PTB.

Current Trends in Nanomaterials-Based Electrochemiluminescence Aptasensors for the Determination of Antibiotic Residues in Foodstuffs: A Comprehensive Review

Veterinary pharmaceuticals have been recently recognized as newly emerging environmental contaminants. Indeed, because of their uncontrolled or overused disposal, we are now facing undesirable amounts of these constituents in foodstuff and its related human health concerns. In this context, developing a well-organized environmental and foodstuff screening toward antibiotic levels is of paramount importance to ensure the safety of food products as well as human health. In this case, with the development and progress of electric/photo detecting, nanomaterials, and nucleic acid aptamer technology, their incorporation-driven evolving electrochemiluminescence aptasensing strategy has presented the hopeful potentials in identifying the residual amounts of different antibiotics toward sensitivity, economy, and practicality. In this context, we reviewed the up-to-date development of ECL aptasensors with aptamers as recognition elements and nanomaterials as the active elements for quantitative sensing the residual antibiotics in foodstuff and agriculture-related matrices, dissected the unavoidable challenges, and debated the upcoming prospects.

Evaluating the effectiveness of Moringa oleifera leaf capsules in controlling glycemic and hypertension levels in type 2 diabetes patients

Moringa oleifera (MO) phytochemicals and therapeutic properties improve hyperglycemia and treat type 2 diabetes. Thus, this study examined the effects of MO leaf capsules on blood glucose management in type 2 diabetic mellitus (T2DM) and hypertension and their safety. A prospective placebo-controlled experiment randomly assigned 24 patients to receive 3g and 6g of MO leaf capsules twice a day or a placebo for three months. Pre- and post-study lab and clinical outcomes were assessed. The placebo control group and 3g MO leaf showed a minor change, whereas 6g and control placebo showed a considerable drop in examined features. MO usage was safe. In T2DM patients, MO leaves lowered blood pressure, requiring further study. MO leaves may help T2DM patients manage blood pressure and blood sugar, according to the study. MO's therapeutic components need more research.